According to Zacks, “AC Immune SA is a biopharmaceutical company. It develops, discover and design novel, proprietary medicines for prevention, diagnosis and treatment of neurodegenerative diseases. The Company’s pipeline includes Crenezumab, ACI-24, Anti-Tau antibody, Morphomer Tau, Tau-PET imaging agent, Morphomer Abeta and Morphomer alpha-syn which are in clinical trial. AC Immune SA is based in Lausanne, Switzerland. “
Separately, SVB Leerink restated a buy rating and set a $17.00 price objective on shares of AC Immune in a research note on Sunday, August 8th.
AC Immune (NASDAQ:ACIU) last issued its quarterly earnings data on Tuesday, August 3rd. The company reported ($0.26) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.02). AC Immune had a negative return on equity of 35.48% and a negative net margin of 405.01%. As a group, equities research analysts expect that AC Immune will post -0.72 earnings per share for the current year.
A number of hedge funds and other institutional investors have recently bought and sold shares of ACIU. JPMorgan Chase & Co. lifted its position in shares of AC Immune by 10,327.3% during the second quarter. JPMorgan Chase & Co. now owns 3,441 shares of the company’s stock worth $27,000 after purchasing an additional 3,408 shares in the last quarter. Bank of America Corp DE lifted its position in shares of AC Immune by 569.9% during the second quarter. Bank of America Corp DE now owns 4,247 shares of the company’s stock worth $34,000 after purchasing an additional 3,613 shares in the last quarter. Citigroup Inc. lifted its position in shares of AC Immune by 221.3% during the second quarter. Citigroup Inc. now owns 4,405 shares of the company’s stock worth $35,000 after purchasing an additional 3,034 shares in the last quarter. Cubist Systematic Strategies LLC acquired a new stake in shares of AC Immune during the second quarter worth about $51,000. Finally, National Asset Management Inc. acquired a new stake in shares of AC Immune during the second quarter worth about $84,000. 25.04% of the stock is currently owned by institutional investors.
AC Immune Company Profile
AC Immune SA engages in the discovery and development of therapeutic and diagnostic products for neurodegenerative diseases. It leverages proprietary technology platforms to discover, design, and develop novel, proprietary medicines for prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding.
Recommended Story: Understanding debt-to-equity ratio in fundamental analysis
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for AC Immune Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AC Immune and related companies with MarketBeat.com's FREE daily email newsletter.